Open AccessHuman embryonic stem cell-derived mesenchymal stem cells improved premature ovarian failure
Author(s) -
Khadijeh Bahrehbar,
Mojtaba Rezazadeh Valojerdi,
Fereshteh Esfandiari,
Rouhollah Fathi,
SeyedehNafiseh Hassani,
Hossein Baharvand
Publication year - 2020
Publication title -
world journal of stem cells
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.907
H-Index - 18
ISSN - 1948-0210
DOI - 10.4252/wjsc.v12.i8.857
Subject(s) - mesenchymal stem cell , stem cell , busulfan , stem cell transplantation for articular cartilage repair , amniotic stem cells , transplantation , premature ovarian failure , biology , embryonic stem cell , stem cell therapy , cancer research , adult stem cell , andrology , medicine , microbiology and biotechnology , endocrinology , hematopoietic stem cell transplantation , biochemistry , gene
Premature ovarian failure (POF) affects many adult women less than 40 years of age and leads to infertility. According to previous reports, various tissue-specific stem cells can restore ovarian function and folliculogenesis in mice with chemotherapy-induced POF. Human embryonic stem cells (ES) provide an alternative source for mesenchymal stem cells (MSCs) because of their similarities in phenotype and immunomodulatory and anti-inflammatory characteristics. Embryonic stem cell-derived mesenchymal stem cells (ES-MSCs) are attractive candidates for regenerative medicine because of their high proliferation and lack of barriers for harvesting tissue-specific MSCs. However, possible therapeutic effects and underlying mechanisms of transplanted ES-MSCs on cyclophosphamide and busulfan-induced mouse ovarian damage have not been evaluated.